Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
In what can only be described as an unexpected finding, a group of German researchers have documented a greater life expectancy for men diagnosed with early stage prostate cancer than for the male population in general, based on data from the Regensburg cancer registry!
Filed under: Diagnosis, Living with Prostate Cancer, Risk, Uncategorized | Tagged: increase, life expectancy, PSA, survival | 6 Comments »
Grace Lu-Yao and colleagues have posted an interesting “Beyond the Abstract” commentary on the UroToday web site in relation to recent data about the associations between obesity and prostate cancer in America.
Filed under: Diagnosis, Risk | Tagged: biopsy, BMI, body mass index, obesity, risk | 2 Comments »
The results of the National Lung Screening Trial were announced yesterday. They show a clear reduction in risk of death from lung cancer among people with a history of heavy smoking. There was a lot of media hoopla.
Filed under: Diagnosis, Risk | Tagged: risk, screening | 7 Comments »
Sometimes there is a piece of research published that provides truly astonishing data for members of the prostate cancer community. The following report is NOT one of these — unless you are a laboratory rat or can appreciate the potential implications for professional, long-distance cyclists.
Filed under: Living with Prostate Cancer | Tagged: ADT, castration, rat | 4 Comments »
Financial disincentives related to prescribing of LHRH agonists introduced in 2003 have clearly been associated with changes in actual physician prescriptions for drugs like Lupron and Zoladex in the immediately following years.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: appropriate use, cost, finance, incentive, LHRH agonist, Medicare | 3 Comments »
A study reported this week in the Archives of Internal Medicine addresses the impact of biochemical recurrence on risk for prostate cancer-specific mortality (PCSM) among a cohort of more than 1,000 US veterans initially diagnosed and treated between 1991 and 1995.
Filed under: Living with Prostate Cancer, Management | Tagged: biochemical recurrence, long-term, outcome, radical prostatectomy, radiotherapy, veteran | 7 Comments »
What people know at the time they make decisions about having tests for risk of specific cancers is important if they are to be able to make truly informed decisions about the value of these tests. That becomes even more important when we consider the pros and cons of annual, mass, population-based cancer screening tests.
Filed under: Diagnosis, Risk | Tagged: knowledge, screening, testing | 5 Comments »
Two new studies just posted on line in the Journal of Clinical Oncology specifically address some of the adverse effects associated with 12 months of continuous androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, adverse effects, androgen deprivation therapy, cognitive, function, physicial | 9 Comments »
A re-analysis of data from the prostate cancer screening arm of the Prostate, Lung, Colon, and Ovarian (PLCO) cancer screening study has now stated that, “Selective use of PSA screening for men in good health appears to reduce the risk of [prostate cancer-specific mortality] with minimal overtreatment.”
Filed under: Diagnosis, Risk | Tagged: comorbidity, healthy, PCLO, re-analysis, screening | 4 Comments »
The potential value of high-intensity focused ultrasound (HIFU) as a treatment for prostate cancer continues to foment controversy between its advocates and its detractors.
Filed under: Management, Treatment | Tagged: HIFU, high-intensity focused ultrasound | Leave a Comment »
Data from the VITAL cohort study do not support the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the chemoprevention of prostate cancer, according to a newly published study.
Filed under: Diagnosis, Prevention, Risk | Tagged: non-steroidal anti-inflammatory agent, NSAID, prevetion | Leave a Comment »
The stream of information about long-term outcomes after brachytherapy continues with an article on 10-year outcomes of high-risk patients treated with brachytherapy, adjuvant external beam radiation, and adjuvant androgen deprivation (ADT).
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "high risk", ADT, androgen deprivation, brachytherapy, external beam radiation therapy, localized, outcome | Leave a Comment »
A recent article in the International Journal of Men’s Health argues that we need to be more honest with patients about the impact of “hormone therapy” in the treatment of prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, castration, emasculation, erectile function, language, masculinity | 14 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site